- cafead Dec 17, 2024 at 12:12: PM
via UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a trial.
The oral asset—dubbed minzasolmin—missed the study’s primary and secondary clinical endpoints, according to a Dec. 16 release.
article source
The oral asset—dubbed minzasolmin—missed the study’s primary and secondary clinical endpoints, according to a Dec. 16 release.
article source